Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors

Cell Reports

Volumn 6, Issue 2, 2014, Pages 377-387

  Janku, Filip ^a   Hong, David S ^a   Fu, Siqing ^a   Piha Paul, Sarina A ^a   Naing, Aung ^a   Falchook, Gerald S ^a   Tsimberidou, Apostolia M ^a   Stepanek, Vanda M ^a   Moulder, Stacy L ^a   Lee, J Jack ^a   Luthra, Rajyalakshmi ^a   Zinner, Ralph G ^a   Broaddus, Russell R ^a   Wheler, Jennifer J ^a   Kurzrock, Razelle ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CONTROL; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GENE; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MAPK GENE; MUTATIONAL ANALYSIS; OVERALL SURVIVAL; PIK3CA GENE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PTEN GENE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; MUTATION; OVARIAN NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; TOR SERINE-THREONINE KINASES;

EID: 84895906492     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2013.12.035     Document Type: Article

References (40)

1. Bader A.G., Kang S., Vogt P.K. Cancer-specific mutations in PIK3CA are oncogenic invivo. Proc. Natl. Acad. Sci. USA 2006, 103:1475-1479.
2. Bang Y.J., Van Cutsem E., Feyereislova A., Chung H.C., Shen L., Sawaki A., Lordick F., Ohtsu A., Omuro Y., Satoh T., et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010, 376:687-697. ToGA Trial Investigators.
3. Cheung L.W., Hennessy B.T., Li J., Yu S., Myers A.P., Djordjevic B., Lu Y., Stemke-Hale K., Dyer M.D., Zhang F., et al. High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov 2011, 1:170-185.
4. Cox D. Regression models and life-tables. J.R. Stat. Soc. B 1972, 34:187-220.
5. De Roock W., Claes B., Bernasconi D., De Schutter J., Biesmans B., Fountzilas G., Kalogeras K.T., Kotoula V., Papamichael D., Laurent-Puig P., et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010, 11:753-762.
6. Di Nicolantonio F., Arena S., Tabernero J., Grosso S., Molinari F., Macarulla T., Russo M., Cancelliere C., Zecchin D., Mazzucchelli L., et al. Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J.Clin. Invest. 2010, 120:2858-2866.
7. Dienstmann R., Serpico D., Rodon J., Saura C., Macarulla T., Elez E., Alsina M., Capdevila J., Perez-Garcia J., Sánchez-Ollé G., et al. Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials. Mol. Cancer Ther. 2012, 11:2062-2071.
8. Dietrich S., Glimm H., Andrulis M., von Kalle C., Ho A.D., Zenz T. BRAF inhibition in refractory hairy-cell leukemia. N.Engl. J. Med. 2012, 366:2038-2040.
9. Druker B.J., Talpaz M., Resta D.J., Peng B., Buchdunger E., Ford J.M., Lydon N.B., Kantarjian H., Capdeville R., Ohno-Jones S., Sawyers C.L. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N.Engl. J. Med. 2001, 344:1031-1037.
10. El-Osta H., Falchook G., Tsimberidou A., Hong D., Naing A., Kim K., Wen S., Janku F., Kurzrock R. BRAF mutations in advanced cancers: clinical characteristics and outcomes. PLoS ONE 2011, 6:e25806.
11. Engelman J.A. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat. Rev. Cancer 2009, 9:550-562.
12. Engelman J.A., Chen L., Tan X., Crosby K., Guimaraes A.R., Upadhyay R., Maira M., McNamara K., Perera S.A., Song Y., et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat. Med. 2008, 14:1351-1356.
13. Faber A.C., Li D., Song Y., Liang M.C., Yeap B.Y., Bronson R.T., Lifshits E., Chen Z., Maira S.M., García-Echeverría C., et al. Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Proc. Natl. Acad. Sci. USA 2009, 106:19503-19508.
14. Faber A.C., Corcoran R.B., Ebi H., Sequist L.V., Waltman B.A., Chung E., Incio J., Digumarthy S.R., Pollack S.F., Song Y., et al. BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors. Cancer Discov 2011, 1:352-365.
15. Falchook G.S., Long G.V., Kurzrock R., Kim K.B., Arkenau T.H., Brown M.P., Hamid O., Infante J.R., Millward M., Pavlick A.C., et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 2012, 379:1893-1901.
16. Flaherty K.T., Puzanov I., Kim K.B., Ribas A., McArthur G.A., Sosman J.A., O'Dwyer P.J., Lee R.J., Grippo J.F., Nolop K., Chapman P.B. Inhibition of mutated, activated BRAF in metastatic melanoma. N.Engl. J. Med. 2010, 363:809-819.
17. Forbes S.A., Bindal N., Bamford S., Cole C., Kok C.Y., Beare D., Jia M., Shepherd R., Leung K., Menzies A., et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 2011, 39(Database issue):D945-D950.
18. Galsky M.D., Von Hoff D.D., Neubauer M., Anderson T., Fleming M., Nagarwala Y., Mahoney J.M., Midwinter D., Vocila L., Zaks T.Z. Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors. Invest. New Drugs 2012, 30:695-701.
19. Gerlinger M., Rowan A.J., Horswell S., Larkin J., Endesfelder D., Gronroos E., Martinez P., Matthews N., Stewart A., Tarpey P., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N.Engl. J. Med. 2012, 366:883-892.
20. Hollander M.C., Blumenthal G.M., Dennis P.A. PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat. Rev. Cancer 2011, 11:289-301.
21. Ihle N.T., Lemos R., Wipf P., Yacoub A., Mitchell C., Siwak D., Mills G.B., Dent P., Kirkpatrick D.L., Powis G. Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res. 2009, 69:143-150.
22. Janku F., Lee J.J., Tsimberidou A.M., Hong D.S., Naing A., Falchook G.S., Fu S., Luthra R., Garrido-Laguna I., Kurzrock R. PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. PLoS ONE 2011, 6:e22769.
23. Janku F., Tsimberidou A.M., Garrido-Laguna I., Wang X., Luthra R., Hong D.S., Naing A., Falchook G.S., Moroney J.W., Piha-Paul S.A., et al. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol. Cancer Ther. 2011, 10:558-565.
24. Janku F., Wheler J.J., Naing A., Stepanek V.M., Falchook G.S., Fu S., Garrido-Laguna I., Tsimberidou A.M., Piha-Paul S.A., Moulder S.L., et al. PIK3CA mutations in advanced cancers: characteristics and outcomes. Oncotarget 2012, 3:1566-1575.
25. Janku F., Wheler J.J., Westin S.N., Moulder S.L., Naing A., Tsimberidou A.M., Fu S., Falchook G.S., Hong D.S., Garrido-Laguna I., et al. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J.Clin. Oncol. 2012, 30:777-782.
26. Janku F., Wheler J.J., Naing A., Falchook G.S., Hong D.S., Stepanek V.M., Fu S., Piha-Paul S.A., Lee J.J., Luthra R., et al. PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. Cancer Res. 2013, 73:276-284.
27. Kaplan E.L., Meier P. Nonparametric estimator from incomplete observations. J.Am. Stat. Assoc. 1958, 53:457-481.
28. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., Harris P.L., Haserlat S.M., Supko J.G., Haluska F.G., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N.Engl. J. Med. 2004, 350:2129-2139.
29. Moroney J.W., Schlumbrecht M.P., Helgason T., Coleman R.L., Moulder S., Naing A., Bodurka D.C., Janku F., Hong D.S., Kurzrock R. A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies. Clin. Cancer Res. 2011, 17:6840-6846.
30. Ng K.P., Hillmer A.M., Chuah C.T., Juan W.C., Ko T.K., Teo A.S., Ariyaratne P.N., Takahashi N., Sawada K., Fei Y., et al. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat. Med. 2012, 18:521-528.
31. Ni J., Liu Q., Xie S., Carlson C., Von T., Vogel K., Riddle S., Benes C., Eck M., Roberts T., et al. Functional characterization of an isoform-selective inhibitor of PI3K-p110β as a potential anticancer agent. Cancer Discov 2012, 2:425-433.
32. Ross R.L., Askham J.M., Knowles M.A. PIK3CA mutation spectrum in urothelial carcinoma reflects cell context-dependent signaling and phenotypic outputs. Oncogene 2013, 32:768-776.
33. Samuels Y., Wang Z., Bardelli A., Silliman N., Ptak J., Szabo S., Yan H., Gazdar A., Powell S.M., Riggins G.J., et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004, 304:554.
34. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., Verweij J., Van Glabbeke M., van Oosterom A.T., Christian M.C., Gwyther S.G. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J.Natl. Cancer Inst. 2000, 92:205-216.
35. Tsimberidou A.M., Iskander N.G., Hong D.S., Wheler J.J., Falchook G.S., Fu S., Piha-Paul S., Naing A., Janku F., Luthra R., et al. Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin. Cancer Res. 2012, 18:6373-6383.
36. Wee S., Wiederschain D., Maira S.M., Loo A., Miller C., deBeaumont R., Stegmeier F., Yao Y.M., Lengauer C. PTEN-deficient cancers depend on PIK3CB. Proc. Natl. Acad. Sci. USA 2008, 105:13057-13062.
37. Wee S., Jagani Z., Xiang K.X., Loo A., Dorsch M., Yao Y.M., Sellers W.R., Lengauer C., Stegmeier F. PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res. 2009, 69:4286-4293.
38. Weigelt B., Warne P.H., Downward J. PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs. Oncogene 2011, 30:3222-3233.
39. Westin J.R., Kurzrock R. It's about time: lessons for solid tumors from chronic myelogenous leukemia therapy. Mol. Cancer Ther. 2012, 11:2549-2555.
40. Zuo Z., Chen S.S., Chandra P.K., Galbincea J.M., Soape M., Doan S., Barkoh B.A., Koeppen H., Medeiros L.J., Luthra R. Application of COLD-PCR for improved detection of KRAS mutations in clinical samples. Mod. Pathol. 2009, 22:1023-1031.